Important breast cancer data will come in the opening months of 2022, and Glaxo and Pfizer are due pivotal RSV results.
Lilly will soon discover whether its purchase of Dermira was wise.
Abbvie expects more Rinvoq data in ulcerative colitis while Astrazeneca takes on myasthenia gravis, and gene therapy is in play for Pfizer and Roche.
As Biogen heads towards important depression data, Sanofi looks to oncology for growth.
But more traditional device makers seem uninterested in this means of stock market listing.